Basic fibroblast growth factor and hematopoiesis.

Abstract:

:Basic fibroblast growth factor (bFGF or FGF-2) is an angiogenic and pleiotropic factor involved in the proliferation and differentiation of numerous cell types. It is expressed mostly in tissues of mesoderm and neuroectoderm origin, and plays an important role in the mesoderm induction, together with transforming growth factor-beta (TGF-beta). Although hematopoietic cells derive from the mesoderm, relatively few studies have addressed the role of bFGF in the hematopoietic system until recently. It appears that bFGF is expressed and produced by bone marrow stromal cells, as well as by cells from several mature peripheral blood lineages. It is released and stored in the bone marrow extra-cellular matrix. FGF-receptors (FGF-Rs) are expressed on nearly every cell of hematopoietic origin tested so far. Growing evidence shows that bFGF can positively regulate hematopoiesis, by acting on various cellular targets: stromal cells, early and committed hematopoietic progenitors, and possibly some mature blood cells. It synergizes with hematopoietic cytokines, or antagonizes the negative regulatory effects of another factor, TGF-beta, thus potentially playing a central role in hematopoiesis.

journal_name

Leukemia

journal_title

Leukemia

authors

Allouche M

subject

Has Abstract

pub_date

1995-06-01 00:00:00

pages

937-42

issue

6

eissn

0887-6924

issn

1476-5551

journal_volume

9

pub_type

杂志文章,评审

相关文献

LEUKEMIA文献大全
  • CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

    abstract::Upregulation of the immunosuppressive cell surface glycoprotein, CD200, is a common feature of acute myeloid leukemia (AML) and is associated with poor patient outcome. We investigated whether CD200 overexpression on AML cells could specifically compromise patient natural killer (NK) cell anti-tumor responses. We foun...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.1

    authors: Coles SJ,Wang EC,Man S,Hills RK,Burnett AK,Tonks A,Darley RL

    更新日期:2011-05-01 00:00:00

  • Expression of the monocyte-specific esterase gene in leukemia-lymphoma cell lines.

    abstract::The expression of the monocyte esterase was examined in a panel of 77 continuous human leukemia-lymphoma cell lines representing all hematopoietic cell lineages and in 16 other cell lines. Accumulation of mRNA, determined by Northern blotting with the cDNA probe HMSE-1, and production of the protein, shown by isoelect...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Uphoff CC,Gignac SM,Metge K,Zschunke F,Radzun HJ,Drexler HG

    更新日期:1993-01-01 00:00:00

  • Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.

    abstract::Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by refractory cytopenias and susceptibility to leukemic transformation. On a subset of MDS patients with deletion of the long arm of chromosome 5 (del(5q)), lenalidomide exerts hematological and cytogenetic effects, but the ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.296

    authors: Matsuoka A,Tochigi A,Kishimoto M,Nakahara T,Kondo T,Tsujioka T,Tasaka T,Tohyama Y,Tohyama K

    更新日期:2010-04-01 00:00:00

  • TCR gamma/delta bearing lymphocytes in peripheral blood of allogenic bone marrow transplanted patients.

    abstract::The presence of two distinct T-cell receptors (TCR) alpha/beta and gamma/delta dimers as well as of the activated T cells was analysed in peripheral blood mononuclear cells from seventeen recipients of allogeneic bone marrow transplants for leukemia and for severe aplastic anemia. Nine of seventeen recipients expresse...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pálóczi K,Poros A,Szelényi J,Hollán SR,Petrányi GG

    更新日期:1992-01-01 00:00:00

  • Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.

    abstract::Single kinase-targeted cancer therapies often failed prolonged responses because cancer cells bypass through alternative routes. In this study, high-throughput kinomic and proteomic approaches enabled to identify aberrant activity profiles in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) that de...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.342

    authors: Kampen KR,Ter Elst A,Mahmud H,Scherpen FJ,Diks SH,Peppelenbosch MP,de Haas V,Guryev V,de Bont ES

    更新日期:2014-03-01 00:00:00

  • Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.

    abstract::Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.354

    authors: Poggi A,Catellani S,Garuti A,Pierri I,Gobbi M,Zocchi MR

    更新日期:2009-04-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract::Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.93

    authors: Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期:2014-10-01 00:00:00

  • Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.

    abstract::Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph+ leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.174

    authors: Ishiyama K,Kitawaki T,Sugimoto N,Sozu T,Anzai N,Okada M,Nohgawa M,Hatanaka K,Arima N,Ishikawa T,Tabata S,Onaka T,Oka S,Nakabo Y,Amakawa R,Matsui M,Moriguchi T,Takaori-Kondo A,Kadowaki N

    更新日期:2017-01-01 00:00:00

  • Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.

    abstract::MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor that is activated as a result of t(6;14)(p25;q32) in multiple myeloma. MUM1 expression is seen in various B-cell lymphomas and predicts an unfavorable outcome in some lymphoma subtypes. To elucidate its role in B-cell ma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403833

    authors: Uranishi M,Iida S,Sanda T,Ishida T,Tajima E,Ito M,Komatsu H,Inagaki H,Ueda R

    更新日期:2005-08-01 00:00:00

  • Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction.

    abstract::We used a modification of the polymerase chain reaction (PCR) to amplify the specific bcr-abl mRNA from 14 patients with chronic myeloid leukemia (CML) who had previously received non T cell depleted allogenic bone marrow transplantation (BMT). Two types of reactions were used: a single step amplification with 5' and ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Delfau MH,Kerckaert JP,Collyn d'Hooghe M,Fenaux P,Laï JL,Jouet JP,Grandchamp B

    更新日期:1990-01-01 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.327

    authors: Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期:2018-04-01 00:00:00

  • Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome.

    abstract::We investigated the expression of P-glycoprotein (P-gp) in 52 adults with de novo acute myelogenous leukemia (AML) at the initial diagnosis. We tested 52 patients by flow cytometry using the MRK16 monoclonal antibody (MoAb). To investigate the phenotype for multidrug resistance, 41 of the patients were analyzed using ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ino T,Miyazaki H,Isogai M,Nomura T,Tsuzuki M,Tsuruo T,Ezaki K,Hirano M

    更新日期:1994-09-01 00:00:00

  • High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

    abstract::Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are largely undefined. T...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.105

    authors: Metzelder SK,Schroeder T,Finck A,Scholl S,Fey M,Götze K,Linn YC,Kröger M,Reiter A,Salih HR,Heinicke T,Stuhlmann R,Müller L,Giagounidis A,Meyer RG,Brugger W,Vöhringer M,Dreger P,Mori M,Basara N,Schäfer-Eckart K,S

    更新日期:2012-11-01 00:00:00

  • Prenatal origin of separate evolution of leukemia in identical twins.

    abstract::Several studies involving identical twins with concordant leukemia and retrospective scrutiny of archived neonatal blood spots have shown that the TEL-AML1 fusion gene in childhood acute lymphoblastic leukemia (ALL) frequently arises before birth. A prenatal origin of childhood leukemia was further supported by the de...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403462

    authors: Teuffel O,Betts DR,Dettling M,Schaub R,Schäfer BW,Niggli FK

    更新日期:2004-10-01 00:00:00

  • Heterogeneity of VH-JH gene rearrangement patterns: an insight into the biology of B cell precursor ALL.

    abstract::Oligoclonal B cell proliferation, as defined by the presence of more than one leukemic clone, has been detected in approximately 20% to 30% of patients with acute lymphoblastic leukemia (ALL) using PCR or Southern blotting. An accurate assessment of these populations is required to avoid false negative measurements of...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402234

    authors: Moreira I,Papaioannou M,Mortuza FY,Gameiro P,Palmisano GL,Harrison CJ,Prentice HG,Mehta AB,Hoffbrand AV,Foroni L

    更新日期:2001-10-01 00:00:00

  • Interferon alpha in the therapy of multiple myeloma.

    abstract::Response rates of 20% were achieved when interferon alpha (IFN) was applied as single agent treatment for multiple myeloma. A synergistic activity was observed when IFN was combined with chemotherapeutic agents in vitro and in vivo. These observations led to a series of randomized trials comparing chemotherapy alone w...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Gisslinger H

    更新日期:1997-12-01 00:00:00

  • A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

    abstract::Retinoids have significant antiproliferative effect against chronic myelogenous leukemia (CML) cells in vitro. We conducted a pilot study to investigate the clinical effect of all-trans retinoic acid (ATRA) in patients with CML. Thirteen patients with Philadelphia chromosome (Ph)-positive CML in late chronic phase (n=...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400682

    authors: Cortes J,Kantarjian H,O'Brien S,Beran M,Estey E,Keating M,Talpaz M

    更新日期:1997-07-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract::Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.283

    authors: Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期:2011-03-01 00:00:00

  • Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

    abstract::Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by ex...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.24

    authors: Hoellenriegel J,Coffey GP,Sinha U,Pandey A,Sivina M,Ferrajoli A,Ravandi F,Wierda WG,O'Brien S,Keating MJ,Burger JA

    更新日期:2012-07-01 00:00:00

  • Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.

    abstract::The fusion transcript AML1/ETO corresponding to translocation t(8;21)(q22;q22) can be found in approximately 7-12% of childhood de novo AML. Despite the favorable prognosis, some of these patients relapse. Most of MRD studies so far were performed on adults treated not uniformly. Therefore, we analyzed the follow-up o...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2402959

    authors: Viehmann S,Teigler-Schlegel A,Bruch J,Langebrake C,Reinhardt D,Harbott J

    更新日期:2003-06-01 00:00:00

  • In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells.

    abstract::Granulocyte-macrophage colony-stimulating factor, (GM-CSF) was given at 8 micrograms/kg daily by continuous i.v. infusion for 72 h to six patients with acute myeloid leukemia (AML) in expansion and one with chronic myeloid leukemia in blastic crisis to determine whether it was possible to augment the proliferative act...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Aglietta M,De Felice L,Stacchini A,Petti MC,Bianchi AC,Aloe Spiriti MA,Sanavio F,Apra F,Piacibello W,Stern AC

    更新日期:1991-11-01 00:00:00

  • Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

    abstract::We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly diagnosed AML were enrolled in 5 prospective treatment trials of the German-Austrian AML Study Group. After fi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.23

    authors: Wattad M,Weber D,Döhner K,Krauter J,Gaidzik VI,Paschka P,Heuser M,Thol F,Kindler T,Lübbert M,Salih HR,Kündgen A,Horst HA,Brossart P,Götze K,Nachbaur D,Köhne CH,Ringhoffer M,Wulf G,Held G,Salwender H,Benner A,G

    更新日期:2017-06-01 00:00:00

  • Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis.

    abstract::Acute leukemias of the t(4;11) (MLL-AF4 fusion gene) type frequently have high white blood counts and extramedullary disease in multiple organs. In the present study we evaluated the hypotheses that this extensive disease is the result of extramedullary survival of leukemia cells due to resistance to stress-induced ce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401148

    authors: Kersey JH,Wang D,Oberto M

    更新日期:1998-10-01 00:00:00

  • Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1.

    abstract::The pH chromosome, resulting from the t(9;22) translocation, is the most frequently observed cytogenetic aberration in acute lymphoblastic leukemia (ALL). Two genes, bcr and abl, are involved in this translocation. As a consequence, parts of the bcr and abl genes are fused, resulting in chimeric bcr-abl genes encoding...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: van Denderen J,ten Hacken P,Berendes P,Zegers N,Boersma W,Grosveld G,van Ewijk W

    更新日期:1994-09-01 00:00:00

  • VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

    abstract::We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403667

    authors: Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

    更新日期:2005-04-01 00:00:00

  • The regulation of hematopoiesis in max 41 transgenic mice with sustained excess granulopoiesis.

    abstract::max 41 transgenic mice consistently exhibit elevated numbers of mature granulocytes and monocytes in the peripheral blood and of immature and mature cells of these lineages in the marrow, spleen, lymph nodes and liver. The immature populations are not autonomous and exhibit a normal quantitative responsiveness to prol...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Metcalf D,Roberts AW,Willson TA

    更新日期:1996-02-01 00:00:00

  • Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.

    abstract::Transcriptional regulation of the HOXA genes is thought to involve CTCF-mediated chromatin loops and the opposing actions of the COMPASS and Polycomb epigenetic complexes. We investigated the role of these mechanisms at the HOXA cluster in AML cells with the common NPM1c mutation, which express both HOXA and HOXB gene...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0856-3

    authors: Ghasemi R,Struthers H,Wilson ER,Spencer DH

    更新日期:2020-05-12 00:00:00

  • A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia.

    abstract::Modern therapy for pediatric acute lymphoblastic leukemia (ALL) is based on the principle of risk stratification. One of the most important laboratory features used to accurately risk stratify patients is the presence of specific chromosomal translocation within the leukemic blasts. In this paper, we describe a multip...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401224

    authors: Scurto P,Hsu Rocha M,Kane JR,Williams WK,Haney DM,Conn WP,Shurtleff SA,Downing JR

    更新日期:1998-12-01 00:00:00

  • Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

    abstract::Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0416-x

    authors: Follo MY,Pellagatti A,Armstrong RN,Ratti S,Mongiorgi S,De Fanti S,Bochicchio MT,Russo D,Gobbi M,Miglino M,Parisi S,Martinelli G,Cavo M,Luiselli D,McCubrey JA,Suh PG,Manzoli L,Boultwood J,Finelli C,Cocco L

    更新日期:2019-09-01 00:00:00

  • Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

    abstract::We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400768

    authors: Matsuo Y,MacLeod RA,Uphoff CC,Drexler HG,Nishizaki C,Katayama Y,Kimura G,Fujii N,Omoto E,Harada M,Orita K

    更新日期:1997-09-01 00:00:00